Document is current
Any future updates will be listed below
-
Authors
Sen Gupta, Sourav
Siegel, Katherine
McNeice, Julianna L.
Outtrim, Esther L.
Jasarevic, Rijalda
Pope, Howard
Alvarez, Alicarmen
Brent, Corbin
Hartley, Amy
Fleischer, Candace C.
da Rocha, Helena Nunez
Costello, Julie
Gopinath, Kaundinya
Easley, Kirk A.
Loring, David W.
Nguyen, Minh Ly
Accardi, Carolyn Jonas
Peterson, Ryan B.
Harrison, Taylor B.
Marconi, Vincent C.
Tyor, William R.
Anderson, Albert M. L.
Gavegnano, Christina
- License Information
-
More Information
Article History
Received: 1 February 2026
Accepted: 27 August 2026
First Online: 10 September 2026
Declarations
Ethics approval and consent to participate {30}: Initial IRB approval document for this study protocol (IRB ID: STUDY 00004498) and the latest approved amendment are attached. The trial consent form used to consent participants enrolled in the study is attached.
Consent for publication: Not applicable.
Competing interests {7b}: The industry sponsor (Eli Lilly and Company) will supply the study drug and matching placebo but no direct monetary or funding support. Emory University holds a patent for the use of Jak inhibitors for treatment of viral infections, including HIV-1. Dr. Gavegnano (co-author) is listed as a co-inventor on this technology. VCM has received investigator-initiated research grants (to the institution) and research support from Eli Lilly, Bayer, Gilead Sciences, Merck, Pfizer, Optinosis, and ViiV. WT has received investigator-initiated research grants (to the institution). Emory University has a financial interest in Eli Lilly and Company due to the use of the IP in this study. The terms of this arrangement have been reviewed and approved by Emory’s Research Institutional Conflict of Interest (ICOI) Committee in accordance with Emory University Policy 7.24 Research Institutional Conflicts of Interest.
